Takeda Pharmaceutical (NYSE:TAK) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a strong sell rating in a research report sent to investors on Monday,Zacks.com reports.

Several other brokerages have also issued reports on TAK. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.2%

Shares of TAK stock opened at $16.02 on Monday. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $16.13 and a two-hundred day moving average price of $16.83. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The firm has a market cap of $50.97 billion, a P/E ratio of 41.07 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. Equities analysts anticipate that Takeda Pharmaceutical will post 0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of large investors have recently bought and sold shares of TAK. Parallel Advisors LLC boosted its position in Takeda Pharmaceutical by 10.5% during the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after buying an additional 2,343 shares during the period. Glenmede Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 9.6% during the first quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock worth $559,000 after purchasing an additional 2,640 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 95.8% during the first quarter. EverSource Wealth Advisors LLC now owns 25,896 shares of the company’s stock worth $480,000 after purchasing an additional 12,669 shares during the period. Royal Bank of Canada boosted its holdings in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after purchasing an additional 60,725 shares during the period. Finally, Quantinno Capital Management LP grew its stake in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.